LOGIN
FREE REPORT
search
times
New call-to-action

Articles

Wall Street rises on oil gains and inflation data

ASR Team

Self-directed investors have relied on Australian Stock Report for over 20 years to provide them with comments on the Australian stock market and useful insights. We provide Australian investors with market news and research to make decisions that would help manage their savings, build a sustainable income, and potentially achieve capital growth.

MRN-Tile_1200x800-17

Image Source: Adobe Stock

 

Morning Research Notes - 30.09.24

 

On Friday, Wall Street closed higher, with the Dow Jones Industrial Average reaching a record high, driven by a surge in energy stocks and positive inflation data. Commodities experienced mixed performance on Friday: Spot gold decreased by 0.5%, settling at US$2,658.24 per ounce. Brent crude rose by 1.1%, bringing its price up to US$72.41 per barrel. Iron ore continued its upward momentum, rising by 4.4% to US$102.85 per tonne.

Wall Street gained on Friday, with the Dow Jones Industrial Average reaching a record high of 42,313.00, gaining 137 points (0.3%). A surge in energy stocks was partly responsible for this rise as oil prices increased amid escalating tensions in the Middle East. Despite a slight decline in tech stocks, investor sentiment was boosted by signs of cooling inflation, with the headline PCE index rising only 0.1% in August. US consumer spending grew by 0.2%, slower than expected, while household income growth also slowed.

Australian markets experienced gains on Friday, with the ASX200 closing 0.10% higher. This trend of mixed performance was evident across major indices. The materials and information technology sectors ended the day positively, closing at 2.78% and 0.4% higher respectively. In contrast, the financials, health care, and utilities sectors closed at 0.63%, 1.32%, and 0.73% lower, respectively. Commodities traded relatively flat, with Zinc and Nickel prices remaining unchanged, while Aluminium ended the day 4.38% higher and Copper closed 0.45% lower.

 

Chart of the day

 

An often overlooked yet highly undervalued sector is healthcare. Healthcare can provide a solid opportunity for defensive diversification. The sector is typically resilient during economic downturns, as demand for medical services and products tends to remain constant. Investing in healthcare can offer a safeguard against market volatility that taps into long-term growth driven by ageing populations, technological advancements and ongoing innovation. Morningstar research shows that nearly 50% of healthcare stocks are rated 4 or 5 stars, indicating they're trading below intrinsic value. 

 

Picture_2__2_-Sep-30-2024-04-20-35-6102-AM
Source: Livewire, Playton


If you want to receive our top 3 income stocks click on the button below:

 



Invest Well,
Australian Stock Report

 

This report has been prepared by Atlantic Pacific Securities Pty Limited trading as ASR Wealth Advisers ABN 72 135 187 085 (“ASRW”) CAR 339207 of Amalgamated Australian Investment Solutions Pty Ltd (AAIS) (AFSL 314 614 - ABN: 61 123 680 106) and distributed with its consent by Australian Stock Report Pty Ltd ABN 94 106 863 978 (ASR) AFSL 301682. ASRW and ASR are part of Amalgamated Australian Investment Group Limited ABN 81 140 208 288. Whilst the information presented herein is believed to be reliable and sourced from public sources thought to be reliable, neither ASRW nor ASR make any representations as to its accuracy or completeness. This report is provided for informational purposes only. It is not an offer or a solicitation of an offer to buy or sell any financial products or to participate in any particular trading strategy. Any advice perceived to be included within this report is provided on a general advice basis only and therefore it does not take into account personal financial situation, objectives and needs of any individual. Before making any decision about financial products, investors must consider whether it is appropriate for them in light of their personal circumstances and seek professional investment, tax, legal and/or personal financial advice. Where applicable, investors should obtain and consider a Product Disclosure Statement, prospectus or other disclosure material relevant to the financial product before making a decision to acquire it.  
ASRW’s, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Opinions, estimates and projections constitute the current judgement of the author as at the date of this report. They do not necessarily reflect the opinions of ASRW or any of their related entities, must not be seen as an endorsement in any way and are subject to change without notice. ASRW has no obligation to update, modify or amend this report or otherwise notify a recipient if any opinion, forecast or estimate contained herein changes or subsequently becomes inaccurate. Target prices are inherently imprecise and a product of the analyst’s judgement. Prices and availability of financial products are subject to change without notice and investment transactions can lead to losses as a result of price fluctuations, extreme volatility and other factors. If a financial product is denominated in a currency other than an investor’s currency, a change in exchange rates may adversely affect the investment.  
Investing in financial markets involves risk and investments may go up and down. The payment of income and the return of capital are not guaranteed. Past performance is not an indicator of future results. Macroeconomic fluctuations often account for most of the risks associated with exposures to instruments that offer fixed or variable interest rates. Upside surprises in inflation, fiscal funding needs, and FX depreciation rates are among the most common adverse macroeconomic shocks that may impact the market value of any investment. Counterparty exposure, issuer creditworthiness, client segmentation, regulation, changes in tax policies, currency convertibility and settlement issues related to local clearing houses are also important risk factors to take into consideration.  
The opinions and recommendations in the research report are based on a reasonable assessment by the research staff member who wrote the report using information provided by the product issuer and generally available in the market. ASRW’s research staff are well qualified and give their opinions and recommendations on reasonable grounds and based on the information available to them. ASRW’s research staff are remunerated by salary and do not receive any commissions or fees. Annual bonuses may be paid on a discretionary basis and as relevant to their role. Employees and/or associates of ASRW, ASR and their related entities may hold one or more of the stocks, securities or investments reviewed in this report. Any personal holdings by employees and/or associates of ASRW, ASR and their related entities should not be seen as an endorsement or recommendation in any way.  For information about ASRW, its financial services and Financial Services Guide, please visit www.asrw.com.au .